Eiger to Present at Cantor 2019 Global Healthcare Conference
A live webcast of the presentation will be available on the
Eiger will also host one-on-one meetings with investors.
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.
The Company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also advancing peginterferon lambda, a first-in-class interferon, toward Phase 3 for the treatment of HDV. Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-to-present-at-cantor-2019-global-healthcare-conference-300926694.html